225 related articles for article (PubMed ID: 18424894)
21. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
22. A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients.
von Gruenigen V; Frasure H; Fusco N; DeBernardo R; Eldermire E; Eaton S; Waggoner S
Cancer; 2010 Oct; 116(20):4735-43. PubMed ID: 20629022
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of two different doses of pyridoxine in the prevention of capecitabine-associated palmar-plantar erythrodysesthesia.
Chalermchai T; Tantiphlachiva K; Suwanrusme H; Voravud N; Sriuranpong V
Asia Pac J Clin Oncol; 2010 Sep; 6(3):155-60. PubMed ID: 20887495
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin-induced palmar-plantar erythrodysestesia in multiple uncommon sites.
Corazza M; Minghetti S; Zauli S; Ricci M; Borghi A; Virgili A
Eur J Dermatol; 2011; 21(3):433-4. PubMed ID: 21515437
[No Abstract] [Full Text] [Related]
25. Topical DMSO treatment for pegylated liposomal doxorubicin-induced palmar-plantar erythrodysesthesia.
Lopez AM; Wallace L; Dorr RT; Koff M; Hersh EM; Alberts DS
Cancer Chemother Pharmacol; 1999; 44(4):303-6. PubMed ID: 10447577
[TBL] [Abstract][Full Text] [Related]
26. Influence of microparticles on the homogeneity of distribution of topically applied substances.
Lademann J; Richter H; Golz K; Zastrow L; Sterry W; Patzelt A
Skin Pharmacol Physiol; 2008; 21(5):274-82. PubMed ID: 18663341
[TBL] [Abstract][Full Text] [Related]
27. Eccrine squamous syringometaplasia secondary to pegylated liposomal doxorubicin.
Garcia-Navarro X; Puig L; Fernández-Figueras MT; Alomar A
Arch Dermatol; 2008 Oct; 144(10):1402-3. PubMed ID: 18936417
[No Abstract] [Full Text] [Related]
28. [Plantar-palmar erythrodysesthesia. A new and relatively frequent side effect in antineoplastic treatment].
Risum S; Langer SW
Ugeskr Laeger; 2003 Aug; 165(33):3161-2. PubMed ID: 12968412
[TBL] [Abstract][Full Text] [Related]
29. Detection of doxorubicin in the horny layer in a patient suffering from palmar-plantar erythrodysaesthesia.
Schmook T; Jacobi U; Lademann J; Worm M; Stockfleth E
Dermatology; 2005; 210(3):237-8. PubMed ID: 15785055
[No Abstract] [Full Text] [Related]
30. Striking follicular eruption to pegylated liposomal doxorubicin.
Dai J; Micheletti R; Rosenbach M; Chu EY
Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
[TBL] [Abstract][Full Text] [Related]
31. Prevention of palmar-plantar erythrodysesthesia with an antiperspirant in breast cancer patients treated with pegylated liposomal doxorubicin (SAKK 92/08).
Templeton AJ; Ribi K; Surber C; Sun H; Hsu Schmitz SF; Beyeler M; Dietrich D; Borner M; Winkler A; Müller A; von Rohr L; Winterhalder RC; Rochlitz C; von Moos R; Zaman K; Thürlimann BJ; Ruhstaller T;
Breast; 2014 Jun; 23(3):244-9. PubMed ID: 24656636
[TBL] [Abstract][Full Text] [Related]
32. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
33. Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with taxotere.
Vukelja SJ; Baker WJ; Burris HA; Keeling JH; Von Hoff D
J Natl Cancer Inst; 1993 Sep; 85(17):1432-3. PubMed ID: 8102408
[No Abstract] [Full Text] [Related]
34. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Markman M; Kulp B; Peterson G
Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
[TBL] [Abstract][Full Text] [Related]
35. Oral dexamethasone attenuates Doxil-induced palmar-plantar erythrodysesthesias in patients with recurrent gynecologic malignancies.
Drake RD; Lin WM; King M; Farrar D; Miller DS; Coleman RL
Gynecol Oncol; 2004 Aug; 94(2):320-4. PubMed ID: 15297168
[TBL] [Abstract][Full Text] [Related]
36. Palmar-plantar erythrodysesthesia syndrome associated with liposomal daunorubicin.
Hui YF; Cortes JE
Pharmacotherapy; 2000 Oct; 20(10):1221-3. PubMed ID: 11034047
[TBL] [Abstract][Full Text] [Related]
37. Pegylated liposomal doxorubicin: a guide to its use in various malignancies.
Lyseng-Williamson KA; Duggan ST; Keating GM
BioDrugs; 2013 Oct; 27(5):533-40. PubMed ID: 24018470
[TBL] [Abstract][Full Text] [Related]
38. Palmar-plantar erythrodysesthesia.
Wilkes GM; Doyle D
Clin J Oncol Nurs; 2005 Feb; 9(1):103-6. PubMed ID: 15751504
[No Abstract] [Full Text] [Related]
39. Serious stomatitis and esophagitis: a peculiar mucous reaction induced by pegylated liposomal doxorubicin.
Ma H; Chen M; Liu J; Li Y; Li J
An Bras Dermatol; 2015; 90(3 Suppl 1):209-11. PubMed ID: 26312719
[TBL] [Abstract][Full Text] [Related]
40. Hand-foot syndrome.
Pike K
Oncol Nurs Forum; 2001; 28(10):1519-20. PubMed ID: 11759299
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
